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ABSTRACT
Objectives: Clinical genetics guidelines from 2011
conceptualise genetic information as confidential to
families, not individuals. The normative consequence
of this is that the family’s interest is the primary
consideration and genetic information is shared unless
there are good reasons not to do so. We investigated
healthcare professionals’ (HCPs’) views about, and
reasoning around, individual and familial approaches to
confidentiality and how such views influenced their
practice.
Method: 16 focus groups with 80 HCPs working in/
with clinical genetics services were analysed, drawing
on grounded theory.
Results: Participants raised seven problems with, and
arguments against, going beyond the individual
approach to confidentiality. These problems fell into
two overlapping categories: ‘relationships’ and
‘structures’. Most participants had never considered
ways to—or thought it was impossible to—treat
familial genetic information and personal information
differently. They worried that putting the familial
approach into practice could disrupt family dynamics
and erode patient trust in the health service. They also
thought they had insufficient resources to share
information and feared that sharing might change the
standard of care and make them more vulnerable to
liability.
Conclusions: A familial approach to confidentiality
has not been accepted or adopted as a standard, but
wider research suggests that some of the problems
HCPs perceived are surmountable and sharing in the
interest of the family can be achieved. However, further
research is needed to explore how personal and
familial genetic information can be separated in
practice. Our findings are relevant to HCPs across
health services who are starting to use genome tests
as part of their routine investigations.
INTRODUCTION
Healthcare professionals (HCPs) frequently
encounter cases where patients have appar-
ently not told family members about a herit-
able risk that is relevant to them. In this
empirical study, we wish to shed light on two
types of these cases: ﬁrst, when the patient
has refused to inform family members or to
give consent to allow HCPs to inform on
their behalf. Second, a potentially more
common problem, where consent is ambigu-
ous: a patient was seen in the past (possibly
some years ago) when they agreed to share
results with relatives but it becomes evident
from a new patient (their relative) that this
has not happened.1 2 Although outright refu-
sals to share information are reportedly
rare,3 patients often delay telling relatives or
state an intention to tell but for some reason
do not.1 2 One might consider that here, the
HCP faces a conﬂict of normative duties and
values: respecting individual conﬁdentiality
and autonomy on one hand and preventing
potential harm to a relative on the other.
A view of conﬁdentiality in which genetic
information is conceptualised as conﬁdential
at the familial rather than the individual
level is the ‘joint account’ (which we here-
after refer to as the ‘familial approach’ for
clarity).4–6 It proposes that potentially familial
genetic information should be available to all
Strengths and limitations of this study
▪ Our study is the first to explore, specifically and
in detail, approaches to confidentiality and
responsibilities to relatives.
▪ It builds on previous work that has interrogated
the familial approach to confidentiality but is
novel in that it has explored views about the
approach using empirical methods.
▪ One limitation is that some discussions were
around hypothetical issues.
▪ Although our qualitative approach does not aim
for generalisability, our findings are transferable.
The details about our research context will
enable other healthcare professionals within and
outside the UK to determine the extent to which
the findings apply to their setting.
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at-risk family members and so HCPs should consider
taking disclosure of this information to relatives as their
default starting position. The question, ‘can we share
the patient’s information?’ is reconsidered as, ‘can we
share the familial genetic information with those to
whom it might be relevant?’ The normative conse-
quence regarding the two cases is that the conﬂict of
duties is reconceptualised: the interest of all those who
might have the inherited ﬁnding is the primary consid-
eration and familial genetic information is shared,
unless there are good reasons not to do so. Current UK
guidelines from the Joint Committee on Medical
Genetics ( JCMG)7 incorporate such a familial approach
and encourage HCPs to discuss family relationships,
communication of information and the types of informa-
tion that might be shared at the time of testing. The
guidance recommends that the onus might be left with
patients to communicate with family in the ﬁrst instance,
but where a HCP realises this has not happened and
there is a beneﬁt to a family member to be had, they
would not be vetoed from sharing the familial genetic
information by lack of explicit consent. Importantly, the
HCP would still need to consider the potential harms
that might arise from sharing this genetic information.
Beneﬁcence, justice and reciprocity underpin this
familial approach. To explain, determining a patient’s
risk requires the patient’s family history to be taken into
account, along with the patient’s signs and symptoms.
Once the patient’s risk status is known, reciprocity
towards those relatives who may not have had the oppor-
tunity for, but might beneﬁt from, genetic testing, may
be appropriate.
Like the JCMG, commentators in the USA have sug-
gested that HCPs should make clear to patients that they
will share information and treat the family, not the indi-
vidual, as their patient.8 9 Australian policy about
genomic research results is comparable: rather than
treating all results as conﬁdential to one person by
default, researchers must make clear that the participant
cannot prevent the sharing of information that could
beneﬁt family members at risk of a serious illness for
which treatment is available or pending.10 Box 1 features
an example of a situation in which a HCP might share
just familial genetic information.
Why explore this now?
Conﬁdentiality and HCPs’ responsibility to relatives in
genetic medicine is ripe for examination. First, usage of
broad approaches to genome analysis, with their greater
pick up rate of heritable ﬁndings (including primary
ﬁndings and secondary/incidental ﬁndings), are on the
increase. A case in point is the UK National Health
Service (NHS), which is setting up a genomic medicine
service in which patients and their families will be
offered whole-exome or whole-genome sequencing as a
frontline test across specialties.11 Often, primary and sec-
ondary/incidental ﬁndings will require testing of close
relatives to determine their clinical signiﬁcance. A boom
in the number of potentially at-risk relatives identiﬁed is
thus imminent, and HCPs will need to consider how
they negotiate conﬁdentiality and communication of
relevant information in this context. Second, the UK has
recently heard its ﬁrst court cases12 13 that considered
whether a duty of care is owed by HCPs to their patients’
relatives. These cases do not shed light on HCPs’ per-
ceived professional and/or moral responsibility to some
relatives, nor whether in some cases one could argue that
HCPs have such a responsibility, because the courts’
arguments focused speciﬁcally on the concept of duty of
care, and whether this duty would be owed to all
relatives.
Although many studies have explored patients’ experi-
ences of, and barriers to, communication within fami-
lies,14 there is currently no empirical research exploring
HCPs’ views about conﬁdentiality in clinical genetics.
The extent to which UK practice has incorporated
guidelines, whether and to what extent the familial
approach is accepted and adopted as a standard, and
the concerns HCPs have about it, are unclear. Previous
research we undertook with patients showed that, to an
extent, they supported the familial approach: partici-
pants thought genetic information was familial that
family members had a ‘right to know’ their risk and that
the range of harms justifying disclosure without clear
consent was broad. Crucially, they wanted HCPs to tell
them about their approach to sharing familial genetic
information at the outset.15 Our recent systematic review
by contrast showed that although HCPs did generally
feel a responsibility towards their patients’ relatives, they
perceived a range of barriers to sharing information.16
They thought doing so could violate the patient’s or the
relative’s privacy; found it difﬁcult to deﬁne medical
beneﬁt and thus whether information warranted disclos-
ure; and perceived a strong obligation to respect the
wishes of the patient who explicitly refused to tell their
family members about a risk. The ﬁndings from this
review are tentative: just nine studies were with HCPs
Box 1 Separating individual and familial genetic informa-
tion in practice
Patient A is seen at time 1. He has had prostate cancer but also
has a family history of breast cancer. A genetic test shows he has
a BRCA2 mutation. Patient B, patient A’s sister, is seen at time
2. There is no evidence that she knows about the BRCA2 muta-
tion but she knows about the family history of breast cancer.
Healthcare professionals (HCPs) can tell patient B, ‘we know your
family history is in part explained by a BRCA2 mutation and we
can test you for it’. This will not say anything about patient A. If,
by any chance, patient B says, ‘do you know this because of my
brother?’, the HCP can reply, ‘we know this because of the
pattern of cancers in your family’. No confidence of personal
information would have been betrayed and nothing about patient
A’s medical diagnosis shared. This action could be taken if
patient A had given consent to share information, if he had
refused consent to share, and if his consent was unclear.
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and none explored conﬁdentiality and responsibility to
relatives speciﬁcally; most used basic surveys; almost all
focussed on cases where patients explicitly refused to tell
their family rather than where consent was ambiguous;
and none explored the concept of distinguishing
genetic information from personal clinical information.
Our study therefore aimed to elicit HCPs’ views about,
reasoning around and conceptual understanding of con-
ﬁdentiality; their perceived responsibility to patients’
relatives; and the way these considerations related to
their practice.
METHODS
Design
This study was qualitative and drew on grounded
theory.17 We chose cross-sectional (one-off) focus
groups. These were with groups working in the same
department where possible to provide an understanding
of the real-life context in which HCPs worked and made
decisions.18
Recruitment and sampling
A NHS Research Ethics Committee approved the
research on 25/02/13 (reference: 13/SC/0041).
Between late 2013 and early 2015, we invited HCPs
involved in genetic testing to take part by presenting the
study aims and protocol at professional meetings and
sending emails with attached information sheets to
heads of departments for dissemination to colleagues.
Sampling was purposive: we tried to recruit from a range
of genetic and afﬁliated services. It is unclear how many
potential participants the information reached and thus
the number who chose not to participate.
Sample and data collection
We designed our topic guide (see box 2) based on the
existing literature. We also used the familial and individ-
ual approaches to conﬁdentiality as our theoretical
framework for the topic guide and for analysis. The
topic guide was semistructured and piloted in the ﬁrst
group. Focus group discussions centred mainly on
patients with risks of cancers and cardiac conditions, for
whom there is often an intervention (eg, treatment,
risk-reducing options or surveillance) and thus where
communication with relatives is most urgent. SD, a
research fellow with a doctorate in health sciences and
several years’ experience of qualitative research in the
ﬁeld, conducted all focus groups alone. SD audio-
recorded the discussions which lasted ∼1 hour, and took
ﬁeld notes of non-verbal aspects of communication,
such as nodding. Participants had no previous relation-
ship with her. Sixteen focus groups with 80 HCPs from
across the UK were conducted, either in clinical depart-
ments or during professional meetings. There were par-
ticipants from 14 of the 24 UK genetic services. Table 1
details participants’ professions.
Data analysis
After the ﬁrst focus group, SD, AL and AF began
coding and thematically analysing the data, drawing on
elements of grounded theory, such as constant compari-
son.17 We independently interrogated transcripts and
then discussed the emerging codes and themes
together. The topic guide was adapted over time to
pursue emerging lines of inquiry. We ceased recruit-
ment and data collection when we began to approach
saturation.
Box 2 Topic guide
Introduction
▸ What is your role?
▸ What kinds of patients do you see? How many per week?
▸ What other departments do you work with?
Confidentiality
Is confidentiality important in the area of medicine that you are
working in?
▸ Why do you think it is important from a patient’s point of
view?
▸ And why from a healthcare professionals’ (HCPs’) perspective?
What aspects of the medical consultation should be kept
confidential?
▸ Probe about personal versus familial genetic information
▸ Probe about confidentiality in genetic medicine versus other
areas of medicine
Are there guidance documents or protocols you follow for
confidentiality?
▸ What do they say?
▸ Are they widely read?
▸ Do people agree with them?
Consent
What does/should the consent process involve when a person
has a genetic test?
▸ Is there an official consent process in your department?
▸ How, if at all, do you talk about the limits of confidentiality in
the consent process?
▸ What do you consider these limits to be?
Information sharing
Regarding genetic test results, who do you think should tell the
result to at-risk relatives?
▸ Probe: the person themselves, a HCP, general practitioner, etc.
▸ Probe: advantages and disadvantages of each.
Have you ever had experience of a patient telling you they were
not going to inform their family of risk? Or a patient who you
were not sure had told?
▸ Probe for details.
To what extent do you feel like you have a responsibility to ensure
patients’ family members know their risk?
▸ What, if any, limits does this responsibility have?
The future
Regarding these issues, do you feel like you have enough support
and training?
Whom do you talk to about ethical issues?
What are your main concerns, if you have any?
Do you have some other things you would like to raise?
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FINDINGS
General outline: the conventional steps for facilitating
communication
Participants questioned their responsibility to their
patients’ relative(s) when consent was ambiguous or
when a patient had refused consent to share informa-
tion. Although participants claimed they rarely encoun-
tered the latter situation, they mentioned around 30
different cases where a relative had not been told.
Furthermore, they recognised that their awareness might
be limited by patients who said they would tell family
members but did not actually do so. When a patient
refused consent or was reluctant to share information,
they had several conventional strategies to encourage
disclosure, outlined in ﬁgure 1, including discussing
cases at the UK Genethics Forum.19 No one reported
contacting relatives or their general practitioners (GPs)
directly, checking databases to ﬁnd relatives’ details or
checking family ﬁles to see if they had been referred—
all of which are strategies that have been used in inter-
vention studies.20–24 A consideration when deciding
what to do was whether the relative was also their patient
or a patient of another genetics service, or whether the
relative had not been referred for genetic advice at all.
Participants said they had gone, or would go, beyond
these conventional steps only in exceptional situations,
for example, if there was a child at risk of an early-onset,
serious and treatable condition.
Rather, they perceived several problems with taking a
familial approach to conﬁdentiality, which fell into two
overlapping themes and subthemes, summarised in
ﬁgure 2. The ﬁrst comprised of concerns about rela-
tionships between family members as well as between
HCPs and patients. The second pertained to the struc-
ture of the health service, comprising practical, legal
and ethical considerations about the distribution of
resources.
Relationships
We cannot always separate familial and personal information
Some participants considered genetic information famil-
ial, but thought disentangling familial information from
the patient’s personal clinical information was not always
possible. Others had not considered whether there was a
difference between personal and familial information.
They thought that even if they told relatives (directly or
via a HCP) that there was a risk in the family, it might
point to a particular person who could then claim that
their conﬁdence had been breached. Many argued this
was more likely than not as they were ‘dealing with rare
conditions and it is quite a small world’ (FG14P4).
Participants reported that some of their patients appar-
ently felt their relatives had no ‘right to know’ (FG12P2)
what they considered ‘their’ diagnosis, even if the diag-
nosis implied an inheritance that had relevance for
these relatives too. As their HCPs’, they thought they
had to respect this view.
Only some participants talked about personal and
familial genetic information as being separable. For
example, one participant recalled a case where a new
patient concerned about his risk for a familial cancer
syndrome had an ‘inkling’ about where distant affected
relatives lived. The participant found an old report
Table 1 Details of focus group participants
Profession Number
Genetic counsellors 37
Clinical scientists (molecular/cytogenetics) 16
Consultants in clinical genetics 8
Registrars (trainees) in clinical genetics 8
Nurses working with a genetics team 4
Fetal medicine professionals 4
Family history coordinators 2
Nephrologist 1
Total 80
FG5, 6 and 7 comprised of participants from different departments.
The rest worked in the same department.
Figure 1 Healthcare
professionals’ conventional ways
of dealing with non-disclosure.
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about one of these relatives where consent was unclear,
and shared just the necessary information:
FG10P3: I got her report…he hardly has any contact with
that family member. He had an inkling who it was. He
didn’t know what kind of cancer she’d had [or] anything.
He wasn’t particularly curious either. All I said to him
was, ‘I’ve done some digging and I’ve found some infor-
mation and we have a test we can offer you’. But I com-
pletely stepped over the issue of who it was, and what
cancer they had.
Along these lines, other participants said that if a HCP
made a considered decision to share some information
carefully, for example, familial genetic information via a
GP, it would not count as a breach:
FG14P6: If you make a decision to write to a [relative’s]
GP or go down these different aisles of trying to get the
information to people, I think breach isn’t quite the
right term to use, because you’re carefully considering
the conﬁdentiality in the situation and there’s different
layers. You’re carefully considering ‘yes, actually we think
it’s appropriate to go to the GP in this situation because
the risk of harm [is] high enough’.
A few participants said they would not feel it was a
breach of conﬁdentiality on their part if the relative
inferred the patient’s identity, as long as they themselves
had not included any identifying information. However,
the potential for inference made many others reluctant
to share familial genetic information. Participants felt
more compelled to do so if the relative had been
referred to them, because they then had a duty of care
to both parties, but even this was tricky work, with many
talking about how ‘careful’ they had to be.
Our contact can disrupt family relationships and cause
distress
Family relationships were a key consideration for partici-
pants when thinking about sharing information. One
reason was that, in their experience, patients who had
not (yet) shared information with relatives often had
poor relationships with them. Some were anxious that
relatives would judge them or were worried about what
relatives would do upon learning the information (eg, a
previous patient of FG3P1, who was diagnosed with
haemophilia, apparently refused to tell her pregnant
sister about the possibly familial risk in case she termi-
nated the pregnancy). Participants felt unable to ascer-
tain these ‘intricacies’ of family dynamics and were
uncomfortable with the uncertain, potentially ‘enormous’
(FG16P1), and exacerbating impact sharing genetic infor-
mation could have. Coupled with their worry about separ-
ating personal and familial genetic information, this
concern led them to err away from sharing information:
FG16P3: [It] really does make me question what responsi-
bility you have and what a mess you could make of that
family by sharing that information…we just don’t know:
you could cause much more psychological damage by dis-
closing. But you’re the keeper of this really difﬁcult piece
of information.
FG16P1: An unknowable risk isn’t it, the damage that
you could cause by disclosing.
Regarding direct contact with relatives, participants
thought it would be more of a shock and more invasive
of privacy if a HCP, as opposed to the patient, made
contact. They were moreover apprehensive about violat-
ing the relative’s ‘right not to know’ and said that
although a patient would also violate this right if they
communicated the information, it was ‘less okay’ for
Figure 2 Themes—each corresponds to an argument against using the familial approach.
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HCPs violate it (FG14P6). Interestingly, participants
were reluctant to contact relatives even in situations
where a patient had speciﬁcally asked them to, as they
thought the information would be better received if
coming from a family member.
A few participants in FG14 criticised some of their own
arguments here, and thought they perhaps should share
familial genetic information, despite their anxieties about
family dynamics. They considered it a double standard to
refuse to invade the privacy of their patient’s relative,
given that it was standard practice to ask patients to
invade the privacy of their relatives (with whom they
might not have a close relationship) and indeed forgo
their own privacy (in that if the patient shared, the rela-
tive would likely realise that they had had the test).
Sharing information could damage patient trust in the NHS
A minority of participants pointed out that by not sharing
familial genetic information, a relative could come to
harm or die, for example from a preventable cancer, and
this might outweigh the potential harms of breaching a
patient’s conﬁdentiality. However, others thought it could
damage a patient’s trust in the health service if a HCP
shared even familial genetic information, which weighed
heavily in the balance against doing so:
FG14P3: Ultimately, I’d worry about keeping [my
patient’s] conﬁdentiality.
FG14P5: Yeah, but not to the detriment of other
people! It’s difﬁcult when you stop to philosophise about
that: where does our responsibility lie? Does it lie with
the family or does it lie with just that patient? It’s a very
difﬁcult moral issue. There’s people out there who could
die because you’re not telling them, because you’re
worried about someone getting in trouble with their
sister. Which is more important? It’s difﬁcult isn’t it?
FG14P3: You don’t want no one ever to come forward
to see a genetics department.
FG14P5: They’d feel worried that information will be…
FG14P3: It’s always going to be shared with everyone.
This concern about trust was underpinned by partici-
pants feeling that it would not be fair for them to share
information when they had not been explicit from the
outset that they could. Indeed, an important ﬁnding was
that while participants considered it a vital part of their
role to highlight familial implications, they did not always
do so in the ﬁrst appointment, thinking it important to
instead give the patient time to understand, cope with
and adjust to their risk or diagnosis. They thought that
sharing familial genetic information without having been
explicit about it at the outset would violate an implicit
social contract and this could in turn damage the rela-
tionship between them:
FG10P1: We say to the patient, ‘it’s your responsibility to
cascade this information in your family. We take no part
in that.’ But when they say they’re not going to do it, and
we say ‘we’re going to step in and do it for you’, that’s
quite tricky.
FG10P5: Also, you say everything you tell is conﬁdential.
FG10P2: apart from (!)
FG10P1: It’s a bit mean for those patients to come
through thinking everything is going to be conﬁdential,
and then for that to backﬁre on them. They’re coming
thinking, ‘this is my information’.
Notably, the focus group discussions made some parti-
cipants reﬂect on their usual consent practices and
question whether they should ask patients to agree to
sharing before testing them.
We assume family members can find out another way
When patients had not yet told relatives about a risk,
participants made hopeful claims that the news would
probably be communicated throughout the family even-
tually. Given this possibility, they did not feel wholly
obliged to intervene:
FG8P2: Maybe those [relatives] will ﬁnd out another way,
because they don’t often fall out with their whole family.
It’s often speciﬁc people. I’ve certainly had people come
to clinic who have found out about the mutation through
some circuitous way.
FG8P3: Yeah, we often get uncoordinated referrals, in
a sense that family members will be referred separately,
so often they don’t know that they’re simultaneously all
being seen. Like you said, the news does go round in
some way or the other.
Participants also considered the possibility that if given
‘dear relative’ letters, patients who were reluctant or
refusing to share information, or to give consent for
HCPs to share, would eventually pass them letters on.
They moreover thought that if a patient did not share
information, an at-risk relative might know their family
history and request independent advice from a genetics
service anyway.
Other participants explicitly acknowledged that these
were all assumptions, and cited several examples where
family members had in fact not learnt about their risk
through other means for many years. And in some fam-
ilies, relatives had developed a cancer that could have
been prevented:
FG14P4: I’m seeing a chap on Thursday. I saw his mum
in about 2002 and said your son can be tested, and he’s
just rocked up now, 12 years later, for a pre-symptomatic
test, and he’s got the mutation. He could have known
that a long time ago.
Structural issues
We usually encourage patients at follow-up appointments
Participants said that in the past, they had taken for
granted that they would have follow-up appointments
with patients to discuss familial communication.
Participants thought these appointments were important
to help patients understand their own and their rela-
tives’ risks, and to facilitate communication:
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FG5P3: The more common reason for non-disclosure is
that the penny hasn’t dropped. You think you’ve
explained it, they nod at you nicely, [yet] they’re like,
‘what about cousin Sue?’ And you’re thinking, ‘we’ve
done this a thousand times!’ We can’t assume that
because it’s easy for us [to understand genetics] it’s easy
for them. It takes ages.
As several groups discussed, follow-ups were becoming
less possible due to health service constraints. Ironically,
these cutbacks were happening concurrent to the increas-
ing use of genome tests, which, as discussed earlier,
produce results of a greater number and complexity:
FG5P2: It’s going to become far more prevalent in our
practice as genetic counsellors to encourage people to
share information and [think about] how to persuade
them to do it. So [genomic medicine] is changing our
role, isn’t it? Yet at the same time, we have less contact on
the whole with patients than we used to have. And the rela-
tionship has changed. So I think it’s very, very challenging.
FG5P1: It’s getting harder and harder to discuss commu-
nication issues and do the bread-and-butter counsellor
stuff a lot of us came into the profession to do, because
there’s the pressure of seeing more and more people
with fewer and fewer resources.
A related problem was that where follow-up appoint-
ments were available, patients did not always use them,
did not ‘know their way through the NHS’ (FG14P1), or
know that ‘the door is open and they can come back if
they want’ (FG16P1). Therefore, patients who had not
told relatives about a risk sometimes had only one
contact with HCPs. Participants realised they could
make ways of accessing help clearer. That participants
had this concern indicated their preference for building
a relationship with the patient and encouraging them to
share information themselves.
We lack the resources for disclosure to relatives and worry
about legal consequences
Participants perceived constrained resources (ie, time,
staff, funding, methods of ﬁnding contact details) a
major barrier to doing anything other than leaving com-
munication entirely up to patients:
FG4P1: There are probably people that we don’t contact
whom we could, if we had more resources, who could
beneﬁt from it. It’s always going to lead to some sort of
inequality. That is a source of some anxiety in terms of
whether we’ve done the best we can for the wider family
and whether we have a duty to do the best we can for the
wider family. The best we can do at the moment is gener-
ally giving information to the person in front of us.
Everything is done through that person. But if our ser-
vices were conﬁgured in a different way, that might not
be the limit of what we could offer.
When asked what they would do if, hypothetically, they
did have the necessary resources, one response was that
they would still be uneasy about contacting at-risk rela-
tives who had not been referred to their service. Sharing
familial genetic information could leave them liable for
invading the relative’s privacy and breaching a patient’s
conﬁdentiality, but not sharing it, despite having the
resources to do so, could leave them liable for negli-
gence. Inadequacy of resources was thus a defence
against culpability for this wider duty:
FG14P8: No-one’s won a case in America yet which is
good. The moment you start saying it is our job to send
these letters out, then we’ve accepted that this is our
responsibility. The culpability is a [worry].
Another area of trepidation was where they would be
expected to draw the limits of familial contact. Once
they contacted one patient, they argued, they might be
seen as having a legal ‘duty to warn’ all at-risk relatives—
a duty they considered would be impossible to fulﬁl:
FG14P8: If you accept some of [the responsibility], are
you accepting more of it?
FG16P1: [It would] set a very difﬁcult precedent. To what
lengths do you go to make sure that information’s been
passed on, and how do you assess that? Logistically, it
would be almost impossible to check out all the relatives
at risk [have] been informed. We are miles away from
having any kind of infrastructure that would support that.
FG8P1: Where would you ever stop then? How many
people would you contact? How far would you go in the
family?
One worry here was about opportunity cost—the time
spent tracing a relative’s GP for example, would mean
less time for seeing new patients.
We need nationwide consensus
Participants’ apprehensions about resources and liability
were underpinned by the perception that taking respon-
sibility for relatives of patients would be a substantial
shift in genetics practice, because keeping individual
patient conﬁdence was the norm, and communicating
with relatives, or their GPs, was not yet ‘culturally accept-
able’ (FG15P5).
Many participants said they were aware of JCMG
guidelines and the familial approach to conﬁdentiality
advocated within, but thought the guidelines had not
shifted practice. Some desired guidelines with clearer
protocols. Some moreover argued that they would be
more comfortable taking the sharing of familial genetic
information as a default position if doing so was wide-
spread practice, where there would be safety in
numbers, better protection from litigation, and equality
in care for patients and families nationwide:
FG15P5: [Any change] would have to be a national one,
so that everybody could sign up to the same process
[with] guidelines that patients could read. Practice could
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[then] change in the direction of us saying to people
before they had a test, ‘part of having a genetic test is the
willingness [to communicate]’. But you’d need a back-
ground of cultural acceptability. I don’t think it could be
down to individual practitioners, because different [fam-
ilies, and] even members of the same family might be
treated very differently.
FG5P3: We do try to help, [but] there’s no protocol for it,
there’s no standard for how you go about it, even though it
[telling relatives] is the right thing to do. It’s very hard. It
goes wrong in ways you can’t anticipate. You’re leaving
yourself very open as well, and you think, ‘am I interfering
with things I shouldn’t be interfering with?’
Participants at the same time perceived guidelines to
have limited utility, because they typically do not cover
every situation and require professional judgement,
which can be difﬁcult to make. Producing a more
detailed guideline was not deemed a simple solution,
particularly since the ‘standard way of reaching a deci-
sion’ in difﬁcult situations was through discussion with
peers rather than deference to guidance (FG1P1).
DISCUSSION
Although a few had shared familial genetic information
from one individual’s test to beneﬁt relatives, partici-
pants in our study took an individual approach to conﬁ-
dentiality in general. Akin to the ﬁndings of our
systematic review,16 participants, although perceiving
that they might have some responsibility to relatives,
identiﬁed several reasons for not acting on this responsi-
bility. One set of reasons related to concerns about rela-
tionships between family members, and between
themselves and their patients. More speciﬁcally, they
thought that if a patient had not told a family member
about a risk, there might be reasons for this relating to
poor family dynamics, and divulging information could
exacerbate these, could cause distress and could cause
patients to lose trust in the NHS. This ﬁrst concern
echoes that of genetics professionals in research from
the USA:25 26 they considered patient-relative relation-
ships and patients’ emotional reactions to be two of the
most inﬂuential considerations in their decisions about
whether to disclose information. These are important
concerns, but notably, research has shown that when
patients do not share information, there can be out-
comes such as disappointment and resentment between
family members, which can reduce family cohesion and
well-being.27–31 HCPs not sharing information could
equally be worse for trust in the health service, because
relatives who develop a preventable cancer, where HCPs
had known about the risk but had chosen not to act,
might question their practices.32
Two issues that underpinned arguments about relation-
ships in our study were that, ﬁrst, most HCPs had not
considered whether familial genetic information and per-
sonal information could be treated differently, or did not
think they could be, and so worried that sharing familial
genetic information would result in their being blamed
for sharing personal information. Second, our participants
did not always discuss sharing with family members at the
outset of their interactions with patients, and thought
sharing information later down the line would jeopardise
trust and perceived transparency. Indeed, research about
sharing medical information in another NHS context—
the UK’s care.data venture—shows that while people value
appropriate and responsible information-sharing—that
which could contribute to a ‘common good’, a lack of
transparency about what information exactly is shared,
with whom, and for what reason, has led to mistrust in
the health service.33
Relating to our second theme, participants worried
that sharing information would be a resource-intensive
activity. They believed this because they thought taking
on a narrow responsibility for some relatives could
change the standard of care and lead to them having to
take responsibility for more relatives. Echoing this
ﬁnding, research with HCPs regarding recent French
legislation, which requires HCPs to offer to write to rela-
tives about their possible genetic risk, showed that parti-
cipants were apprehensive about what this legislation
would mean for their responsibility to relatives. It was
not clear to them who counts as family, to whom they
would have a responsibility or how this responsibility
could be properly discharged.34 These ﬁndings suggest
that deﬁnitions need to be clearer. Our participants also
argued that if the standard of care were to change, they
could be liable for not sharing information with all
at-risk family members as well as for breaching individual
conﬁdentiality. This may be due to a perceived ‘litigation
culture’ in the health service.
Participants thought that if they were to share familial
genetic information by default, all HCPs should do so,
as part of a consensus shift in practice. This point was
interesting, because with their guidelines, the JCMG7
intended to change practice in this way—that is, encour-
age HCPs to discuss sharing of familial genetic informa-
tion from the outset and make clear why such sharing
was needed and that such sharing could happen. It may
be that HCPs were unsure how to implement the guide-
lines, or that they were unaware who else had taken the
approach on board and were reluctant to be the ﬁrst to
do so. HCPs’ difﬁculties with guidelines have been illu-
strated elsewhere: research from the Netherlands35 and
the USA25 26 has shown that HCPs were unsure what
guidelines existed and as a result, made conservative
assumptions about what sharing was permitted. Thus,
more detailed guidelines are not always the answer—
especially as they will always allow room for professional
judgement, and may lead to inaction, for example, if the
particulars of a certain situation are different to the
ones outlined.36
Although only some participants had considered
taking a familial approach to conﬁdentiality, participants
were more consistent in taking a relational approach to
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autonomy.37 38 According to Gilbar,37 a HCP who is
faced with a disclosure dilemma and is taking this rela-
tional approach would not only consider clinical factors
(eg, whether the risk in question is severe, likely and
has an available intervention), but also the effect of dis-
closure on family relationships. Gilbar also argues that if
taking seriously this last criterion, HCPs will have dis-
cussed “various aspects of the patient’s familial relation-
ships…[and] have close knowledge” of their nature
(p391). In our study, participants saw it as an important
part of their role to highlight familial implications of
any test result. They also considered family relationships
when thinking about ways that information might be
shared, such as via intermediaries. But, ultimately, they
thought patients should share the information.
Implications for practice and research
We would argue that a familial approach to conﬁdential-
ity could be taken as the norm—that is, familial genetic
information could be shared unless there are good reasons
not to—where a result in one person might be relevant to
others. Nevertheless, some important issues relating to par-
ticipants’ concerns would need to be addressed and clari-
ﬁed before engaging a familial approach:
▸ Further research should explore whether separating
personal and familial genetic information is possible
in cases where there is concern about breaching con-
ﬁdentiality, and in what situations sharing the latter
could lead to inference of a patient’s identity.
▸ We recommend that any responsibility HCPs have to
relatives be bounded—that is, their responsibility to
certain relatives should not imply a duty of care or a
duty to warn to all possible at-risk relatives. Having a
default position of sharing familial genetic informa-
tion would then change practice only in narrow cir-
cumstances (ie, where the known relative of a patient
faces harm and/or could beneﬁt from an interven-
tion). Resource-light ways to contact relatives not yet
referred to a genetics service would need to be identi-
ﬁed, such as using existing databases and registers to
ﬁnd their contact details, or those of their GP,
sending tailored letters directly, and making follow-up
phone calls.20–24
▸ We reiterate the JCMG recommendation that HCPs
broach with patients from the earliest opportunity
(eg, before the test) whether and how genetic in-
formation might be shared with family members.
This is especially important since our previous
research showed that patients want HCPs to tell them
at the outset about the possibility of such sharing.16
Since participants considered a relational approach to
autonomy to be standard practice, and since some had
taken a familial approach to conﬁdentiality in some
cases, taking the familial approach as default may simply
be an extension of these existing practices. HCPs
sharing familial genetic information could be more pro-
tective of patient privacy than the family-mediated
approach: patients in one US study illustrated this point,
arguing that HCPs can be trusted to make a distinction
between familial information (eg, the genetic mutation)
and personal clinical information and share accordingly.
Relatives tasked with sharing might not always do so and
might, as a result, reveal patient identities.39 Indeed, in
several published interventions about hereditary
cancers, HCPs have safeguarded individual privacy when
writing to relatives on a patient’s behalf, by simply saying
that a member of the family had been found to have an
inherited tendency to develop cancer, without initially
revealing the gene mutation or speciﬁc diagnosis.20–24
In one of these interventions, clinicians asked relatives if
they thought their privacy was thereby invaded, and
notably, they did not.24
Strengths and weaknesses
Our study is the ﬁrst to explore familial conﬁdentiality
and HCPs’ responsibilities to relatives. The ﬁndings
support our systematic review:16 participants identiﬁed
several reasons for not acting on a perceived responsibil-
ity to relatives. The study builds on previous work that
has interrogated the familial approach, but is novel in
that it has explored views about the approach using
empirical methods.
There were 11 genetics services from which no HCPs
took part. Nevertheless, our ﬁndings are still transfer-
able: we have provided enough detail about our research
context to enable other genetics services within and
outside the UK to determine the extent to which the
ﬁndings apply to their setting.40 One limitation is that
some discussions were around hypothetical issues (eg,
asking what participants would do if resources and infra-
structure were in place). Our wider research is building
on this limitation by using longitudinal research to iden-
tify ethical issues as they are experienced in practice.
CONCLUSIONS
Overall, this study makes an important and timely contri-
bution to what is known about conﬁdentiality and
information-sharing practices at a time when whole-
genome analyses are being offered to increasing numbers
of patients, in the UK and worldwide. More patients will
now be identiﬁed as at risk of a heritable condition, and
more HCPs will be tasked with communicating this infor-
mation to patients. We found that participants consider
the familial approach to conﬁdentiality difﬁcult to imple-
ment in practice. Further research should explore with
HCPs whether they consider the barriers they identiﬁed
surmountable and should explore ways to facilitate the
appropriate and secure sharing of familial genetic infor-
mation to beneﬁt families in practice.
Twitter Follow Sandi Dheensa @sandi_dheensa
Acknowledgements The authors thank everyone who participated, Clinical
Ethics and Law at Southampton, and the reviewers whose comments have
helped to improve the manuscript.
Dheensa S, et al. BMJ Open 2017;7:e012443. doi:10.1136/bmjopen-2016-012443 9
Open Access
Contributors SD conducted the focus groups and led on data analysis and
writing the manuscript. AL and AF facilitated data analysis and provided
critical feedback on several drafts of the manuscript. AL co-authored the
original papers about the joint account approach that framed this work.
Funding This work was supported by the Wellcome Trust: grant number
110486/Z/15/Z.
Competing interests None declared.
Ethics approval Approved by Hampshire B NRES committee south central
(13/SC/0041) on 25/02/13.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://
creativecommons.org/licenses/by/4.0/
REFERENCES
1. Hodgson J, Metcalfe S, Gaff C, et al. Outcomes of a randomised
controlled trial of a complex genetic counselling intervention to
improve family communication. Eur J Hum Genet 2016;24:356–60.
2. Gilbar R. The passive patient and disclosure of genetic information:
can English tort law protect the relatives’ right to know? Int J Law
Policy Fam 2016;30:79–104.
3. Clarke A, Richards M, Kerzin-Storrar L, et al. Genetic professionals’
reports of nondisclosure of genetic risk information within families.
Eur J Hum Genet 2005;13:556–62.
4. Parker M, Lucassen A. Genetic information: a joint account? BMJ
2004;329:165–7.
5. Lucassen A, Parker M. Confidentiality and sharing genetic
information with relatives. Lancet 2010;375:1507–9.
6. Parker M, Lucassen A. Concern for families and individuals in
clinical genetics. J Med Ethics 2003;29:70–3.
7. Joint Committee on Medical Genetics. Consent and confidentiality
in genetic practice. London: Royal College of Physicians and Royal
College of Pathologists, 2011.
8. Doukas DJ, Berg JW. The family covenant and genetic testing.
Am J Bioethics 2001;1:2–10.
9. Knoppers BM. Genetic information and the family: are we our
brother’s keeper? Trends Biotech 2002;20:85–6.
10. Branum R, Wolf SM. International policies on sharing genomic
research results with relatives: approaches to balancing privacy with
access. J Law Med Ethics 2015;43:576–93.
11. Genomics England. The 100,000 genomes project. England:
Genomics England, 2016 (cited 22 March 2016). http://www.
genomicsengland.co.uk/the-100000-genomes-project/
12. ABC v St George’s Healthcare NHS Trust (2015) EWHC 1394 (QB),
(2015) MHLO 39. 2016. http://www.bailii.org/ew/cases/EWHC/QB/
2015/1394.html (cited 12th January 2017).
13. Smith & Anor v University of Leicester NHS Trust [2016] EWHC
817. 2016. http://www.bailii.org/ew/cases/EWHC/QB/2016/817.html
(cited 12th January 2017).
14. Wiens ME, Wilson BJ, Honeywell C, et al. A family genetic risk
communication framework: guiding tool development in genetics
health services. J Community Genet 2013;4:233–42.
15. Dheensa S, Fenwick A, Lucassen A. ‘Is this knowledge mine and
nobody else’s? I don’t feel that’. Patient views about consent,
confidentiality and information-sharing in genetic medicine. J Med
Ethics 2016;42:174–9.
16. Dheensa S, Fenwick A, Shkedi-Rafid S, et al. Health-care
professionals’ responsibility to patients’ relatives in genetic medicine:
a systematic review and synthesis of empirical research. Genet Med
2015;18:290–301.
17. Corbin J, Strauss A. Basics of qualitative research: techniques and
procedures for developing grounded theory. Sage Publications,
2014.
18. Barbour R. Doing focus groups. Sage Publications, 2008.
19. Lucassen A, Parker M. The UK Genethics Club: clinical ethics
support for genetic services. Clin Ethics 2006;1:219–23.
20. Aktan-Collan K, Haukkala A, Pylvänäinen K, et al. Direct
contact in inviting high-risk members of hereditary colon cancer
families to genetic counselling and DNA testing. J Med Genet
2007;44:732–8.
21. Evans DG, Binchy A, Shenton A, et al. Comparison of
proactive and usual approaches to offering predictive testing for
BRCA1/2 mutations in unaffected relatives. Clin Genet
2009;75:124–32.
22. Forrest LE, Burke J, Bacic S, et al. Increased genetic counseling
support improves communication of genetic information in families.
Genet Med 2008;10:167–72.
23. Sermijn E, Goelen G, Teugels E, et al. The impact of proband
mediated information dissemination in families with a BRCA1/2 gene
mutation. J Med Genet 2004;41:e23.
24. Suthers GK, Armstrong J, McCormack J, et al. Letting the family
know: balancing ethics and effectiveness when notifying relatives
about genetic testing for a familial disorder. J Med Genet
2006;43:665–70.
25. Dugan RB, Wiesner GL, Juengst ET, et al. Duty to warn at-risk
relatives for genetic disease: genetic counselors’ clinical experience.
Am J Med Genet A 2003;119:27–34.
26. Falk MJ, Dugan RB, O’Riordan MA, et al. Medical geneticists’ duty
to warn at-risk relatives for genetic disease. Am J Med Genet A
2003;120:374–80.
27. Forrest K, Simpson SA, Wilson BJ, et al. To tell or not to tell: barriers
and facilitators in family communication about genetic risk. Clin
Genet 2003;64:317–26.
28. Gilbar R. Medical confidentiality and communication with the
patient’s family: legal and practical perspectives. CFLQ
2012;24:199–222.
29. Vavolizza RD, Kalia I, Aaron KE, et al. Disclosing genetic
information to family members about inherited cardiac arrhythmias:
an obligation or a choice? J Genet Couns 2015;24:608–15.
30. Klitzman RL. Am I My Genes? Confronting fate and family secrets in
the age of genetic testing. Oxford University Press, 2012.
31. Metcalfe A, Plumridge G, Coad J, et al. Parents’ and children’s
communication about genetic risk: a qualitative study, learning from
families’ experiences. Eur J Hum Genet 2011;19:640–6.
32. Wilcke JT, Seersholm N, Kok-Jensen A, et al. Transmitting genetic
risk information in families: attitudes about disclosing the identity of
relatives. Am J Med Genet A 1999;65:902–9.
33. Sterckx S, Rakic V, Cockbain J, et al. “You hoped we would sleep
walk into accepting the collection of our data”: controversies
surrounding the UK care.data scheme and their wider relevance for
biomedical research. Med Health Care Philos 2016;19:177–90.
34. D’Auffriet Van Haecke D, de Montgolfier S. Genetic test results and
disclosure to family members: qualitative interviews of healthcare
professionals’ perceptions of ethical and professional issues in
France. J Genet Couns 2016;25:483–94.
35. Stol YH, Menko FH, Westerman MJ, et al. Informing family members
about a hereditary predisposition to cancer: attitudes and practices
among clinical geneticists. J Med Ethics 2010;36:391–5.
36. Fenwick A. Are guidelines for genetic testing of children necessary?
Fam Cancer 2010;9:23–5.
37. Gilbar R. Communicating genetic information in the family: the
familial relationship as the forgotten factor. J Med Ethics
2007;33:390–3.
38. Widdows H. Between the individual and the community: the
impact of genetics on ethical models. New Genet Soc
2009;28:173–88.
39. Pentz RD, Peterson SK, Watts B, et al. Hereditary nonpolyposis
colorectal cancer family members’ perceptions about the duty to
inform and health professionals’ role in disseminating genetic
information. Genet Test 2005;9:261–8.
40. Kuper A, Lingard L, Levinson W. Critically appraising qualitative
research. BMJ 2008;337:687.
10 Dheensa S, et al. BMJ Open 2017;7:e012443. doi:10.1136/bmjopen-2016-012443
Open Access
